The Lions Eye Institute (LEI) is strengthening its ties with Indonesian researchers following the successful launch of a new glaucoma drainage device produced for only one-tenth of the cost of competing products. Read more
Biogen unveils plan to commercialise Eylea and Lucentis generics
Multinational biotech company Biogen has proposed a deal worth up to US$310 million (AU$453 m) to supply biosimilar treatments of Lucentis and Eylea to major global markets, including Australia. Read more
Traces of anti-VEGF drugs found in breast milk
Anti-vascular endothelial growth factor (anti-VEGF) drugs have been identified in breast milk, prompting warnings from the researchers that the use of these medications during breastfeeding could affect developing infants. Read more
DFV signs distribution deal for E-Eye dry eye device
Designs For Vision (DFV) has become the new Australian distributor of the E-Eye intense regulated pulsed light (IRPL) device for dry eye disease and meibomian gland dysfunction. Read more
Image of trabecular meshwork captured for the first time
Using the same technique that prevents stars from ‘twinkling’ in telescopic images, researchers have captured the first undistorted microscopic images of the trabecular meshwork. Read more
Eye injections top of agenda for ‘scope of practice’ advisory group
Optometrists performing intravitreal injections is one of several key issues to be addressed by a newly formed Optometry Australia (OA) advisory committee established to identify future opportunities for the profession. Read more
German manufacturer licenses BHVI algorithms for new device
The Brien Holden Vision Institute (BHVI) has signed a licensing agreement that will see its algorithms for tracking and estimating refractive error incorporated into a world-first instrument for myopia management. Read more
Melbourne study to put new AMD tools under microscope
The University of Melbourne is recruiting optometrists to test new clinical tools, as well as an auditing system, it has developed for management of patients with age-related macular degeneration (AMD). Read more
FDA clears Novartis’ new treatment for nAMD
Novartis has secured US regulatory approval for Beovu, the company’s latest therapy for neovascular age-related macular degeneration (nAMD), following the drug’s comparable results in head-to-head trials with Eylea. Read more
Perth partnership targets childhood blindness and $1 billion market
The Lions Eye Institute (LEI) has signed a commercial partnership that will combine its antisense gene therapy for a leading cause of childhood blindness with a new Australian-developed drug delivery platform. Read more